Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence

Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer and predominantly develops in patients with liver cirrhosis. In patients with advanced disease, such as extra-hepatic extension or portal vein involvement, and with intermediate disease unsuitable for locoregional therapies, sy...

Descripción completa

Detalles Bibliográficos
Autores principales: De Luca, Emmanuele, Marino, Donatella, Di Maio, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246316/
https://www.ncbi.nlm.nih.gov/pubmed/32547208
http://dx.doi.org/10.2147/CMAR.S216220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246316/
https://www.ncbi.nlm.nih.gov/pubmed/32547208
http://dx.doi.org/10.2147/CMAR.S216220

Ejemplares similares